샘플 요청 목록

 카트 문의
시장보고서
상품코드
1362395

분자진단 시장 규모 및 예측, 세계 및 지역별 점유율, 동향, 성장 기회 분석 보고서 범위 : 질병 영역별, 기술별, 제품 및 서비스별, 최종 사용자별, 지역별

Molecular Diagnostics Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease Area, Technology, Product & Services, End User, and Geography
발행일: | 리서치사: The Insight Partners | 페이지 정보: 영문 272 Pages | 배송안내 : 즉시배송

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

분자진단제 시장 규모는 2022년 181억 7,387만 달러에서 2030년 458억 7,565만 달러에 달할 것으로 예상되며, 2022-2030년간 12.3%의 CAGR을 나타낼 것으로 예측됩니다. 이 보고서는 시장 동향과 분자진단 의약품 시장의 성장을 가속하고 저해하는 요인에 대해 설명합니다. 시장 성장은 신제품 시장 개척, 현장 검사 수요 증가, 관련 질환의 급증에 기인합니다. 그러나 분자검사의 한계가 시장 성장의 걸림돌로 작용하고 있습니다.

개인맞춤형 의료에서 분자진단 시장의 향후 성장 전망

고처리량 기술의 발전으로 게놈 연구가 더욱 편리하고 비용 효율적일 수 있게 되었습니다. 분자 진단학은 실험실 조건에서 미생물을 배양해야 했던 기존 검사들과는 달리, 이러한 키트와 검사들은 빠른 검출 결과를 제공하기 때문에 임상 실험실에서 점점 더 필수적인 요소가 되고 있습니다. 정밀의학(Precision Medicine)은 환자 개개인의 유전적 체질, 생활습관, 환경 등을 기반으로 환자 개개인에 맞는 치료와 개입을 하는 것을 말합니다. 분자진단학은 이러한 접근법에서 중요한 역할을 합니다. 환자의 치료 결정에 영향을 미치는 특정 바이오마커, 유전자 돌연변이, 유전자 발현 패턴을 식별할 수 있기 때문입니다. 의약품 개발은 점점 더 분자 진단학에 의존하고 있습니다. 스크리닝, 검출, 진단, 치료, 이질성 평가, 진행 계획 수립, 분자 특성 검토, 환자 결과 모니터링 등 다양한 분자 이미징 기술이 활용되고 있습니다. 또한, 분자 이미징은 미세한 종양을 탐지하고 그 활동을 평가하는 데 도움이 되며, 종양학에서 개인 맞춤형 의료, 연구, 임상시험 및 진료의 발전과 확장에 크게 기여하고 있습니다. 하이스루풋 유전체 분석 플랫폼은 임상 샘플에서 유전자 이상을 검출할 수 있으며, 차세대 시퀀싱을 통해 암을 유발하는 모든 유형의 변화를 식별할 수 있습니다. 이러한 기술을 임상에 도입하면 각 환자의 분자 표적을 식별할 수 있고, 질병의 분자적 진행을 쉽게 추적할 수 있습니다. 이러한 접근법을 통해 암 환자들은 개인 맞춤형 치료를 받을 수 있게 됩니다. 이처럼 기술의 발전과 함께 분자진단 시장의 미래는 밝다고 할 수 있습니다.

분자 검사에 따른 한계가 시장 성장을 저해하는 요인으로 작용합니다.

분자 검사 결과는 샘플링, 검사 프로세스, 기술자의 기술력 등에 따라 달라질 수 있기 때문에 검사 결과에 차이가 있을 수 있습니다. 또한, 일부 검사 절차는 결과가 나오기까지 시간이 걸릴 수 있습니다. 검사 키트가 위양성 또는 위음성을 나타낼 수도 있습니다. 이처럼 분자 검사와 관련된 불확실성은 특히 생명을 위협하는 질병의 진단과 치료에 있어 분자 검사의 보급을 가로막고 있습니다. 특히 신흥국 및 저개발 국가에서 현장 검사에 대한 인식이 제한적이라는 점도 시장 성장에 걸림돌이 되고 있습니다. 또한, 암이나 바이러스 감염과 같은 적응증에 대한 분자 검사의 비용과 공급 부족도 분자진단 시장의 성장을 저해하는 요인으로 작용하고 있습니다.

분자진단 시장, 질병 영역별 인사이트

분자진단 시장은 질병 영역별로 암, 감염, 유전자 검사, 심장질환, 면역계 질환, 기타로 구분됩니다.

감염병 분야는 2022년 가장 큰 시장 점유율을 차지했습니다. 그러나 암 분야는 예측 기간 동안 12.6%로 가장 높은 CAGR을 기록할 것으로 예상됩니다. 종양 분자진단은 유전물질, 단백질, 관련 분자를 노출시켜 종양학적 정보를 제공하는 DNA, RNA, 단백질을 기반으로 대사 기능, 약물 대사, 질병 유발을 평가하는 검사입니다. 세계보건기구(WHO)의 발표에 따르면 2020년 암으로 인한 사망자 수는 약 1,000만 명에 달할 전망입니다. 또한 미국암협회의 2021년 통계에 따르면, 2040년까지 세계 암 발병률은 2,750만 명의 신규 환자와 1,630만 명의 암 사망자로 늘어날 것으로 예상됩니다. 이러한 높은 수치는 암 발생 빈도 증가가 원시적 진단과 예방 치료에 대한 가속화 된 요구에 영향을 미치고 있음을 보여줍니다. 암을 진단하는 방법은 PCR, INAAT, NGS 등 여러 가지가 있습니다. 그중 PCR(중합 효소 연쇄반응)의 발상은 임상 DNA 검사에 큰 진전을 가져 왔으며, PCR 기반 방법론은 간단한 장비와 인프라가 필요하고 미량의 생물학적 물질을 사용하기 때문에 임상 루틴에 광범위하게 조화를 이룰 수 있습니다.

PCR의 비용은 높지만, 가장 정확한 실시간 PCR법(정확도 99% 이상)은 한국을 포함한 많은 선진국에서 실제로 사용되고 있습니다. 다른 선택지는 비싸기 때문에 저개발 국가에서는 일반적으로 Rapid PCR(60-70% 정확도)이 사용되고 있습니다. 종양 분자진단 분야에서 NGS는 가장 높은 성장률을 보이는 기술이기도 합니다. 많은 기업들이 이 기술을 경제적으로 활용하기 위해 열심히 노력하고 있습니다. 예를 들어, 2021년 4월 Illumina Inc.는 Kartos Therapeutics와 NGS 기반 TP53 동반 진단을 공동 개발하기 위해 제휴를 맺었습니다고 발표했습니다.

분자 진단 시장, 기술 기반 통찰력

기술별로 분자진단 시장은 중합효소 연쇄반응, 등온 핵산 증폭 기술, DNA 시퀀싱 및 차세대 시퀀싱, DNA 마이크로어레이, in-situ 하이브리드화, 기타로 구분되며, PCR은 RT-PCR, qPCR, 멀티플렉스 PCR, 기타로 세분화된다, PCR 분야는 2022년 시장에서 가장 큰 점유율을 차지할 것으로 예상되며, 예측 기간 동안 12.7%의 가장 높은 CAGR을 기록할 것으로 예상되며, PCR은 주로 핵산 사슬을 복사하여 DNA를 만들고 증폭하는 데 사용됩니다. 열 사이클러는 효소, 뉴클레오티드, 새로운 DNA를 만들기 위한 완충액과 같은 시약과 함께 증폭 중에 DNA 사슬을 변성하고 어닐링하는 데 사용됩니다. 이 기술은 유전자 기능 분석, 유전성 진단, DNA 클로닝, 친자 확인, 감염성 질환 검출, 법의학 등 다양한 응용 분야에 널리 사용되고 있습니다. 중합효소 연쇄반응은 전통적인 PCR, 실시간 PCR, 디지털 PCR로 분류됩니다. 그러나 현재 진행 중인 기술 발전과 팬데믹으로 인한 수요 급증은 인도뿐만 아니라 기타 아시아태평양 국가에서도 PCR 검사에 대한 수요를 계속 증가시킬 것으로 보입니다. 결핵, 간염, 독감, 심각한 전염병과 같은 질병의 지속적인 유행은 PoC 분자진단 산업의 추세를 촉진할 것으로 보입니다. 현재 신종 코로나19의 발생은 이 접근법이 질병의 징후를 보이지 않는 개인의 바이러스를 검출하는 데 매우 중요하기 때문에 시장에 유리한 성장 국면을 조성할 것으로 보입니다.PCR의 절묘한 감도, 상대적 편의성 및 비용 효율성으로 인해 PCR은 다른 핵산 증폭 기술과 차별화됩니다. PCR은 PCR 기술의 지속적인 연구 개발을 통해 다양한 임상 및 진단 응용 및 검사에 필수적인 도구가 되었으며, PCR은 분자 실험실의 주요 기술로 확고한 위치를 차지하고 있습니다. 따라서 PCR은 다양한 감염성 질환에 대한 신속한 현장 진단에 많은 기회를 제공합니다. 예를 들어, F. Hoffmann-La Roche Ltd는 디지털 PCR(dPCR) 기술의 발전을 위해 지속적으로 노력하고 있으며, dPCR은 임상 분야로의 응용을 확대하여 중요한 임상 도구로 부상했습니다. 전염병이 발생했을 때, Mylab PathoDetect COVID-19 Qualitative PCR 키트는 지난해 중앙의약품표준관리기관(CDSCO)으로부터 국내 최초로 상업적 승인을 받았습니다. 승인 후 마이랩은 생명공학 대기업 Serum Institute of India 및 현지 기업 AP Globale과 협력하여 PCR을 RT-PCR, qPCR, 멀티플렉스 PCR 및 기타로 세분화했습니다. 분자진단 시장, 구매 모드별 인사이트.

분자 진단 시장은 제품 및 서비스별로 분석 및 키트, 기기, 서비스 및 소프트웨어로 분류됩니다. 분석 및 키트 시장은 2022년에 가장 큰 점유율을 차지하고 예측 기간 동안 가장 높은 CAGR을 기록할 것으로 예상됩니다. 분자 진단 분석은 널리 사용되는 분석 방법 중 하나입니다. 신속 분자 분석, 역전사 중합효소 연쇄반응(RT-PCR), 항원 등 다양한 유형의 분석이 코로나19, 결핵 등 다양한 질병을 식별하고 분석하는 데 사용되고 있습니다. 제품 혁신 및 비즈니스 전략의 일환으로 시장 기업은 다양한 테스트 키트에 대한 진단 키트를 제공합니다. 지역 업체들은 이 부문과 관련된 사업 개발에 적극적으로 참여하고 있습니다. 예를 들어, 2021년 9월 Mylab Discovery Solutions는 약 70개의 검사를 포인트에서 실행할 수 있는 플랫폼 Swayam a point of care testing system의 개발자인 Sanskritech의 과반수 지분을 인수했습니다. 또한, 코로나19 팬데믹 상황에서 다양한 세계 시장 기업들이 지역 사업부를 통해 키트를 제공합니다. 이러한 요인으로 인해 이 분야는 예측 기간 동안 눈에 띄는 기여를 할 것으로 예상됩니다.

최종 사용자를 기준으로 분자 진단 시장은 병원 및 클리닉, 진단 실험실, 연구 및 학술 기관, 기타로 분류되며, 2022년에는 진단 실험실 부문이 시장에서 가장 큰 점유율을 차지할 것으로 예상됩니다. 또한 이 부문은 2022-2030년간 12.7%의 가장 빠른 CAGR로 수요가 증가할 것으로 예상됩니다. 진단 실험실은 분자 진단 제품 및 서비스의 주요 응용 분야입니다. 이 시설은 규제 요건에 따라 확립된 시설을 갖추고 있습니다. 실험실은 가능한 모든 분자 진단 제품 및 서비스를 사용합니다. 환자에서 채취한 샘플은 다양한 장비, 시약, 방법 및 기술을 사용하여 분석 및 연구합니다. 검사실은 병원, 진료소, 재택의료 등에 서비스를 제공합니다. 만성 질환과 감염성 질환 증가, 개별 연구자들의 분자 진단 활동의 아웃소싱은 예측 기간 동안 이 분야의 성장을 뒷받침하는 요인 중 하나입니다.

분자진단 시장 경쟁 구도 및 주요 발전

Abbott Laboratories, Agilent Technologies Inc, Danaher, Siemens Healthineers AG, Novartis AG, TBG Diagnostics Limited 등이 분자진단 시장에서 사업을 전개하는 주요 기업입니다.

시장 기업들은 새로운 제품을 시장에 출시하고 있습니다. 다음은 그 중 한 가지 예이다:

2023년 1월, 애질런트는 퀘스트 다이애그노스틱스(Quest Diagnostics)와 제휴하여 Agilent Resolution ctDx FIRST 액체 생검 검사에 대한 접근성을 확대합니다. 퀘스트와 애질런트의 협약에 따라 워싱턴의 Resolution Bioscience CLIA 연구소에서 수행되는 단일 사이트 시판 전 승인(ssPMA) 테스트인 ctDx FIRST가 널리 채택될 예정입니다.

2023년 7월, 써모피셔는 분자 진단 실험실을 위한 새로운 소프트웨어를 발표했습니다. 이 소프트웨어는 일상적인 진단 검사를 표준화하고 신속한 결과를 얻기 위해 간소화하는 데 도움이 됩니다. 이 소프트웨어는 워크플로우 단계를 단일 인터페이스 내에서 연결하여 빠르게 변화하는 검사 환경에 동적으로 대응할 수 있는 실험실의 잠재력을 높일 수 있습니다.

2021년 10월, 애질런트 테크놀로지스는 Ki-67 IHC MIB-1 pharmDx(Dako Omnis)가 내분비 요법과 함께 베르제니오(Abemaciclib)를 병용하는 수술 후 보조요법 대상인 조기 유방암(EBC) 환자의 재발 위험이 높은 환자를 식별하기 위한 보조 보조제로 FDA의 승인을 받았다고 밝혔습니다.

목차

제1장 서론

제2장 주요 요약

  • 주요 인사이트

제3장 조사 방법

  • 조사 범위
  • 2차 조사
  • 1차 조사

제4장 분자진단 시장 구도

  • PEST 분석
    • 북미의 PEST 분석
    • 유럽의 PEST 분석
    • 아시아태평양의 PEST 분석
    • 중남미의 PEST 분석
    • 중동 및 아프리카 PEST 분석

제5장 분자진단 시장 역학 : 주요 산업 역학

  • 주요 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회
  • 향후 동향
  • 영향 분석

제6장 분자진단 시장 - 세계 시장 분석

  • 분자진단 시장 매출, 2022년-2030년

제7장세계의 분자진단 시장 - 2030년까지 매출과 예측-질환 영역별

  • 2022년 및 2030년 분자진단 시장 질환 영역별 매출 점유율(%)
  • 암 영역
  • 감염증
  • 유전자 검사
  • 심장 질환
  • 면역계 질환
  • 기타

제8장 세계의 분자진단 시장 - 2030년까지 매출과 예측-기술별

  • 2022년 및 2030년 분자진단 시장 기술별 판매량 점유율(%)
  • 중합효소 연쇄반응
  • 등온 핵산 증폭 기술(INAAT)
  • DNA 시퀀싱 및 차세대 시퀀싱(NGS)
  • DNA 마이크로어레이
  • In-Situ Hybridization (ISH)
  • 기타

제9장 세계의 분자진단 시장 - 2030년까지 매출과 예측-제품 및 서비스별

  • 2022년 및 2030년 분자진단 시장 제품 및 서비스별 판매량 점유율(%)
  • 어세이 및 키트
  • 기기
  • 서비스 및 소프트웨어

제10장세계의 분자진단 시장 : 최종사용자별 매출과 2030년까지 예측

  • 2022년 및 2030년 분자진단 시장 최종사용자별 매출 점유율(%)
  • 병원 및 진료소
  • 진단 실험실
  • 연구기관 및 학술기관
  • 기타

제11장 분자진단 시장 - 지역별 분석

  • 북미
    • 미국
    • 캐나다
    • 멕시코
  • 유럽
    • 독일
    • 영국
    • 프랑스
    • 이탈리아
    • 스페인
    • 기타 유럽
  • 아시아태평양
    • 중국
    • 일본
    • 인도
    • 호주
    • 한국
    • 싱가포르
    • 말레이시아
    • 필리핀
    • 태국
    • 인도네시아
    • 베트남
    • 기타 아시아태평양
  • 중동 및 아프리카
    • 아랍에미리트(UAE)
    • 사우디아라비아
    • 남아프리카공화국
    • 기타 중동 및 아프리카
  • 중남미
    • 브라질
    • 아르헨티나
    • 기타 중남미

제12장 COVID-19 전후의 영향

  • COVID-19 전후의 영향

제13장 분자진단 시장 업계 상황

  • 시장 진출기업 성장 전략(%)
  • 유기적 전개
  • 무기적 전개

제14장 분자진단 시장, 주요 기업 개요

  • Abbott Laboratories
  • Agilent Technologies Inc
  • Thermo Fisher Scientific Inc
  • F. Hoffmann-La Roche Ltd
  • Qiagen NV
  • bioMerieux SA
  • Illumina Inc
  • Danaher
  • Siemens Healthineers AG
  • Novartis AG
  • TBG Diagnostics Limited

제15장 부록

LSH 23.10.24

The molecular diagnostics market size is expected to reach US$ 45,875.65 million by 2030 from US$ 18,173.87 million in 2022; it is estimated to register a CAGR of 12.3% from 2022 to 2030. The report highlights trends prevailing in the market and the factors driving and hindering the molecular diagnostics market growth. The growth of the market is attributed to the development of new products and increase in demand for point-of-care testing and surging prevalence of associated diseases. However, limitations associated with molecular testing hinders the market growth.

Molecular Diagnostics in Personalized Medicine for Molecular Diagnostics Market Growth in the Upcoming Years

With progress in high-throughput techniques, genome research has become more convenient and cost effective. Molecular diagnostics is becoming increasingly indispensable in clinical laboratories as these kits and tests provide rapid detection results as opposed to the conventional tests, which also involved culturing microbes in laboratory conditions in some cases. Using precision medicine, medical treatments and interventions are tailored to each patient based on their unique genetic makeup, lifestyle, and environment. Molecular diagnostics plays an important role in this approach, as it enables the identification of specific biomarkers, genetic mutations, and gene expression patterns that impact decision-making related to the treatment of patients. Drug development has become increasingly dependent on molecular diagnostics. A wide range of molecular imaging techniques are used in screening, detecting, diagnosing, treating, and assessing heterogeneity; making progression plans; examining molecular characteristics; and monitoring patient outcomes. In addition, molecular imaging can aid in the detection of tiny tumors and assessment of their activities, contributing significantly to the development and expansion of personalized medicine, research, clinical trials, and medical practice in oncology. A high-throughput genotyping platform can be used to detect genetic aberrations in clinical samples, and next-generation sequencing can be used to identify all types of cancer-causing changes. The introduction of these techniques into clinical practice would enable the identification of molecular targets in each patient, along with facilitating the tracking of the molecular progression of diseases. With these approaches, cancer patients will be able to receive personalized medicine. Thus, with technology ever evolving, the market for molecular diagnostics seems to have a bright future.

Limitations Associated with Molecular Testing Hampers the Market Growth

The outcomes of molecular testing depend on sampling and testing processes, technicians' skill sets, etc., which may lead to variations in test results. Further, some test procedures take longer for producing results. Several times, test kits may show false positive or negative results. Thus, uncertainties associated with molecular tests hamper their adoption, especially in diagnostics and treatment of life-threatening diseases. The limited awareness of point-of-care tests, particularly in developing and underdeveloped countries, also hinders the market growth. In addition, the cost of molecular testing for indications such as cancer and viral infections, and the shortage of supplies are hampering the molecular diagnostics market.

Molecular Diagnostics Market, By Disease Area Insights

Based on disease area, the molecular diagnostics market is segmented into oncology, infectious disease, genetic testing, cardiac diseases, immune system disorders, and others.

The infectious disease segment held the largest market share in 2022. However, oncology segment is anticipated to register the highest CAGR of 12.6% during the forecast period. Oncology molecular diagnostics are tests that expose inherited material, proteins, associated molecules and assess metabolic functions, drug metabolism, and disease induction grounded on DNA, RNA, and proteins that deliver oncological information. As stated by World Health Organization (WHO), cancer reckoned for roughly 10 million demises in 2020. Furthermore, as per the 2021 statistics by the American Cancer Society, by 2040, the global burden of carcinoma is anticipated to raise to 27.5 million fresh cases and 16.3 million cancer deceases. Such like high figures denote that the evaluated rising frequency of cancer is chipping into the accelerating requirement for primitive diagnosis and preventive cure. There are numerous methods to diagnose carcinoma comprehending PCR, INAAT, and NGS etc. Among all the conception of PCR (polymerase chain reaction) led to an enormous advancement in clinical DNA testing. PCR-based methodologies demand straightforward instrumentation and infrastructure, exploit only minute quantities of biological material and are extensively harmonious with clinical routine.

Although the cost of PCR is lofty, most accurate real-time PCR approach (with more than 99% accuracy) is the one substantially used in numerous developed countries including Korea, while developing countries substantially exploit the conventional PCR (more than 90% accuracy), which is affordable than real-time PCR. Because of the high prices of the other options, underdeveloped countries generally use Rapid PCR (60 - 70% accuracy). Within the field of oncology molecular diagnostics, NGS is another technology flaunting the loftiest rate of growth. Numerous companies are working intensely to make economic use of this technology. For instance, in April 2021, Illumina Inc. blazoned its partnership with Kartos Therapeutics to co-develop an NGS- Based TP53 Companion Diagnostic, which aided to reduce the costs associated with storing and managing of genomic data.

Molecular Diagnostics Market, By Technology-Based Insights

Based on technology, the molecular diagnostics market is segmented into polymerase chain reaction, isothermal nucleic acid amplification technology, DNA sequencing & Next-Generation sequencing, DNA microarrays, in-situ hybridization, and others. The PCR is further sub segmented into RT-PCR, qPCR, Multiplex PCR, and others. The PCR segment held the largest share of the market in 2022, and the same segment is anticipated to register the highest CAGR of 12.7% in the market during the forecast period. PCR is mainly used to make or amplify DNA by copying the nucleic acid strands. Thermal cyclers are employed to denature and anneal DNA strands during amplification, along with reagents such as enzymes, nucleotides, and buffers to build the novel DNA. This technique is widely used in various application such as functional analysis of genes, diagnosis of hereditary, DNA cloning, paternity testing, detection of infectious diseases, and forensic sciences. Polymerase chain reaction has been classified into traditional PCR, real-time PCR, and digital PCR. However, ongoing technological advances and surging demand amid the pandemic will continue to fuel the need for PCR tests in India as well as other Asia Pacific countries. Consistent prevalence of diseases like tuberculosis, Hepatitis, flu, and serious infections will foster PoC molecular diagnostic industry trends. Presently, the outbreak of novel COVID-19 pandemic would create lucrative growth aspects for the market as this approach is highly critical to detect virus in individuals who exhibit no symptoms of signs of disease. PCR's exquisite sensitivity, relative simplicity, and cost-effectiveness makes PCR stand apart from other nucleic acid amplification techniques, cementing it as a mainstay in molecular laboratories. PCR has become an indispensable tool for various clinical and diagnostic applications or examinations due to continuous research & development on PCR technologies. Therefore, it offers many opportunities for rapid point-of-care diagnostics for various infectious diseases. For instance, F. Hoffmann-La Roche Ltd is continuously working on the advancements of Digital PCR (dPCR) techniques. dPCR has extended its applications to the clinical field and has emerged as an important clinical tool. dPCR offers ultrasensitive and absolute nucleic acid quantification without reference standard. Thus, it offers a broader aspect for standardizing and comparing results between laboratories.During pandemic outbreak, one of the first mover startup, Mylab PathoDetect COVID-19 Qualitative PCR kit was among the first in the country to receive commercial approval from the Central Drugs Standard Control Organisation (CDSCO) last year. Following the approval, Mylab had partnered with biotech giant Serum Institute of India and local firm AP Globale. PCR is further sub-segmented into RT-PCR, qPCR, multiplex PCR and others. Molecular Diagnostics Market, By Purchase Mode-Based Insights.

Based on product & services, the molecular diagnostics market is segmented into assays & kits, instruments, and services & software. The assays and kits segment are held the largest share of the market in 2022, and it is anticipated to register the highest CAGR in the market during the forecast period. Molecular Diagnostics assays are among the widely used technique for analysis. Various types of assays such as rapid molecular assays, reverse transcription-polymerase chain reaction (RT-PCR), antigens, and others are used to identify and analyze various diseases such as influenza COVID 19, tuberculosis, and others. As part of product innovation and business strategies, the market players offer diagnostic kits for different test kits. The regional players are actively involved in business development related to the segment. For instance, In September 2021, Mylab Discovery Solutions acquired a majority stake in Sanskritech, developer of a platform Swayam a point of care testing system that can perform about 70 tests on the point. Moreover, in the COVID19 pandemic, various global market players offer their kits through their regional business divisions. Based on the above factors, the segment is expected to contribute remarkably during the forecast period.

Based on end user, the molecular diagnostics market is segmented into hospitals & clinics, diagnostic laboratories, research & academic institutions, and others. In 2022, the diagnostic laboratories segment held the largest share of the market. Moreover, the segment is also expected to witness growth in its demand at a fastest CAGR of 12.7% during 2022 to 2030, owing to the rise in the detection and diagnosis of various medical conditions across the regions. Diagnostic laboratories are the primary uses for molecular diagnostics products and services. It has well-established facilities as per the regulatory requirements. The laboratories use all possible molecular diagnostic products and services. The sample collected from the patients is analyzed and studied using different instruments, reagents, methods, and technologies. The labs provide services to hospitals, clinics, at-home care, and others. The increasing prevalence of chronic diseases, infectious diseases, outsourcing the molecular diagnostics activities by individual researchers are among the factors supporting the segment growth during the forecast period.

Molecular Diagnostics Market: Competitive Landscape and Key Developments

Abbott Laboratories, Agilent Technologies Inc., Thermo Fisher Scientific Inc, F. Hoffman-La Roche Ltd., Qiagen NV, bioMerieux SA, Illumnia Inc., Danaher, Siemens Healthineers AG, Novartis AG, and TBG Diagnostics Limited are among the leading companies operating in the molecular diagnostics market.

Market players are launching new products to the market. Below are few instances:

In January 2023, Agilent to Collaborate with Quest Diagnostics to Extend Access to the Agilent Resolution ctDx FIRST Liquid Biopsy Test. The agreement between Quest and Agilent will enable broad adoption for ctDx FIRST, a single-site premarket approved (ssPMA) test performed at the Resolution Bioscience CLIA laboratory in Washington.

In July 2023, Thermo Fisher launched new software for molecular diagnostics labs. This software helps in streamlining routine diagnostics testing for standardization and rapid time-to-results. It can enhance the potential of a lab to dynamically respond to quickly changing testing environments by connecting workflow steps within a single interface.

In October 2021, Agilent Technologies Inc. has announced its Ki-67 IHC MIB-1 pharmDx (Dako Omnis) is now FDA approved as an aid in identifying patients with early breast cancer (EBC) at high risk of disease recurrence, for whom adjuvant treatment with Verzenio (abemaciclib) in combination with endocrine therapy.

Reasons to Buy:

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the molecular diagnostics market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the global molecular diagnostics market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Molecular Diagnostics Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
    • 4.2.1 North America PEST Analysis
    • 4.2.2 Europe PEST Analysis
    • 4.2.3 Asia Pacific PEST Analysis
    • 4.2.4 South & Central America PEST Analysis
    • 4.2.5 Middle East & Africa PEST Analysis

5. Molecular Diagnostics Market - Key Industry Dynamics

  • 5.1 Key Market Drivers:
    • 5.1.1 Development of New Products and Increase in Demand for Point-of-Care Testing
    • 5.1.2 Surging Prevalence of Associated Diseases
  • 5.2 Market Restraints
    • 5.2.1 Limitations Associated with Molecular Testing
  • 5.3 Market Opportunities
    • 5.3.1 Advancements in Molecular Diagnostics Technologies
  • 5.4 Future Trends
    • 5.4.1 Molecular Diagnostics in Personalized Medicine
  • 5.5 Impact Analysis:

6. Molecular Diagnostics Market - Global Market Analysis

  • 6.1 Molecular Diagnostics Market Revenue (US$ Mn), 2022 - 2030

7. Global Molecular Diagnostics Market - Revenue and Forecast to 2030 - by Disease Area

  • 7.1 Overview
  • 7.2 Molecular Diagnostics Market Revenue Share, by Disease Area 2022 & 2030 (%)
  • 7.3 Oncology
    • 7.3.1 Overview
    • 7.3.2 Oncology: Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Infectious Disease
    • 7.4.1 Overview
    • 7.4.2 Infectious Disease: Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.5 Genetic Testing
    • 7.5.1 Overview
    • 7.5.2 Genetic Testing: Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.6 Cardiac Diseases
    • 7.6.1 Overview
    • 7.6.2 Cardiac Diseases: Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.7 Immune System Disorders
    • 7.7.1 Overview
    • 7.7.2 Immune System Disorders: Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.8 Others
    • 7.8.1 Overview
    • 7.8.2 Others: Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)

8. Global Molecular Diagnostics Market - Revenue and Forecast to 2030 - by Technology

  • 8.1 Overview
  • 8.2 Molecular Diagnostics Market Revenue Share, by Technology 2022 & 2030 (%)
  • 8.3 Polymerase Chain Reaction
    • 8.3.1 Overview
    • 8.3.2 PCR: Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
      • 8.3.2.1 RT-PCR
        • 8.3.2.1.1 Overview
    • 8.3.3 RT-PCR: Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
      • 8.3.3.1 qPCR
        • 8.3.3.1.1 Overview
    • 8.3.4 PCR: Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
      • 8.3.4.1 Multiplex PCR
        • 8.3.4.1.1 Overview
    • 8.3.5 Multiplex PCR: Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
      • 8.3.5.1 Others
        • 8.3.5.1.1 Overview
    • 8.3.6 Others: Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Isothermal Nucleic Acid Amplification Technology (INAAT)
    • 8.4.1 Overview
    • 8.4.2 Isothermal Nucleic Acid Amplification Technology (INAAT): Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.5 DNA Sequencing and Next-Generation Sequencing (NGS)
    • 8.5.1 Overview
    • 8.5.2 DNA Sequencing and Next-Generation Sequencing (NGS): Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.6 DNA Microarrays
    • 8.6.1 Overview
    • 8.6.2 DNA Microarrays: Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.7 In-Situ Hybridization (ISH)
    • 8.7.1 Overview
    • 8.7.2 In-Situ Hybridization (ISH): Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.8 Others
    • 8.8.1 Overview
    • 8.8.2 Others: Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)

9. Global Molecular Diagnostics Market - Revenue and Forecast to 2030 - by Product and Services

  • 9.1 Overview
  • 9.2 Molecular Diagnostics Market Revenue Share, by Product and Services 2022 & 2030 (%)
  • 9.3 Assays and Kits
    • 9.3.1 Overview
    • 9.3.2 Assays and Kits: Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.4 Instruments
    • 9.4.1 Overview
    • 9.4.2 Instruments: Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.5 Services and Software
    • 9.5.1 Overview
    • 9.5.2 Services and Software: Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)

10. Global Molecular Diagnostics Market - Revenue and Forecast to 2030 - by End User

  • 10.1 Overview
  • 10.2 Molecular Diagnostics Market Revenue Share, by End User 2022 & 2030 (%)
  • 10.3 Hospitals and Clinics
    • 10.3.1 Overview
    • 10.3.2 Hospitals and Clinics: Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.4 Diagnostics Laboratories
    • 10.4.1 Overview
    • 10.4.2 Diagnostics Laboratories: Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.5 Research and Academic Institutes
    • 10.5.1 Overview
    • 10.5.2 Research and Academic Institutes: Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.6 Others
    • 10.6.1 Overview
    • 10.6.2 Others: Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)

11. Molecular Diagnostics Market - Geographical Analysis

  • 11.1 North America Molecular Diagnostics Market, Revenue And Forecast To 2030
    • 11.1.1 Overview
    • 11.1.2 North America Molecular Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
    • 11.1.3 North America Molecular Diagnostics Market, by Disease Area
    • 11.1.4 North America Molecular Diagnostics Market, by Technology
      • 11.1.4.1 North America Molecular Diagnostics Market, by Polymerase Chain Reaction (PCR)
    • 11.1.5 North America Molecular Diagnostics Market, by Product and Services
    • 11.1.6 North America Molecular Diagnostics Market, by End User
      • 11.1.6.1 North America Molecular Diagnostics Market, by Country
    • 11.1.7 US
      • 11.1.7.1 Overview
    • 11.1.8 US Molecular Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
    • 11.1.9 US Molecular Diagnostics Market, by Disease Area
    • 11.1.10 US Molecular Diagnostics Market, by Technology
      • 11.1.10.1 US Molecular Diagnostics Market, by Polymerase Chain Reaction (PCR)
    • 11.1.11 US Molecular Diagnostics Market, by Product and Services
    • 11.1.12 US Molecular Diagnostics Market, by End User
    • 11.1.13 Canada
      • 11.1.13.1 Overview
    • 11.1.14 Canada Molecular Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
    • 11.1.15 Canada Molecular Diagnostics Market, by Disease Area
    • 11.1.16 Canada Molecular Diagnostics Market, by Technology
      • 11.1.16.1 Canada Molecular Diagnostics Market, Polymerase Chain Reaction (PCR)
    • 11.1.17 Canada Molecular Diagnostics Market, by Product and Services
    • 11.1.18 Canada Molecular Diagnostics Market, by End User
    • 11.1.19 Mexico
      • 11.1.19.1 Overview
    • 11.1.20 Mexico Molecular Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
    • 11.1.21 Mexico Molecular Diagnostics Market, by Disease Area
    • 11.1.22 Mexico Molecular Diagnostics Market, by Technology
      • 11.1.22.1 Mexico Molecular Diagnostics Market, Polymerase Chain Reaction (PCR)
    • 11.1.23 Mexico Molecular Diagnostics Market, by Product and Services
    • 11.1.24 Mexico Molecular Diagnostics Market, by End User
  • 11.2 Europe Molecular Diagnostics Market, Revenue And Forecast to 2030
    • 11.2.1 Overview
    • 11.2.2 Europe Molecular Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
    • 11.2.3 Europe Molecular Diagnostics Market, by Disease Area
    • 11.2.4 Europe Molecular Diagnostics Market, by Technology
      • 11.2.4.1 Molecular Diagnostics Market, Polymerase Chain Reaction (PCR)
    • 11.2.5 Europe Molecular Diagnostics Market, by Product and Services
    • 11.2.6 Europe Molecular Diagnostics Market, by End User
      • 11.2.6.1 Europe Molecular Diagnostics Market by Country
    • 11.2.7 Germany
      • 11.2.7.1 Overview
    • 11.2.8 Germany Molecular Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
    • 11.2.9 Germany Molecular Diagnostics Market, by Disease Area
    • 11.2.10 Germany Molecular Diagnostics Market, by Technology
      • 11.2.10.1 Germany Molecular Diagnostics Market, Polymerase Chain Reaction (PCR)
    • 11.2.11 Germany Molecular Diagnostics Market, by Product and Services
    • 11.2.12 Germany Molecular Diagnostics Market, by End User
    • 11.2.13 UK
      • 11.2.13.1 Overview
    • 11.2.14 UK Molecular Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
    • 11.2.15 UK Molecular Diagnostics Market, by Disease Area
    • 11.2.16 UK Molecular Diagnostics Market, by Technology
      • 11.2.16.1 UK Molecular Diagnostics Market, Polymerase Chain Reaction (PCR)
    • 11.2.17 UK Molecular Diagnostics Market, by Product and Services
    • 11.2.18 UK Molecular Diagnostics Market, by End User
    • 11.2.19 France
      • 11.2.19.1 Overview
    • 11.2.20 France Molecular Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
    • 11.2.21 France Molecular Diagnostics Market, by Disease Area
    • 11.2.22 France Molecular Diagnostics Market, by Technology
      • 11.2.22.1 France Molecular Diagnostics Market, Polymerase Chain Reaction (PCR)
    • 11.2.23 France Molecular Diagnostics Market, by Product and Services
    • 11.2.24 France Molecular Diagnostics Market, by End User
    • 11.2.25 Italy
      • 11.2.25.1 Overview
    • 11.2.26 Molecular Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
    • 11.2.27 Italy Molecular Diagnostics Market, by Disease Area
    • 11.2.28 Italy Molecular Diagnostics Market, by Technology
      • 11.2.28.1 Italy Molecular Diagnostics Market, Polymerase Chain Reaction (PCR)
    • 11.2.29 Italy Molecular Diagnostics Market, by Product and Services
    • 11.2.30 Italy Molecular Diagnostics Market, by End User
    • 11.2.31 Spain
      • 11.2.31.1 Overview
    • 11.2.32 Spain Molecular Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
    • 11.2.33 Spain Molecular Diagnostics Market, by Disease Area
    • 11.2.34 Spain Molecular Diagnostics Market, by Technology
      • 11.2.34.1 Spain Molecular Diagnostics Market, Polymerase Chain Reaction (PCR)
        • 11.2.34.1.1 Spain Molecular Diagnostics Market, by Product and Services
    • 11.2.35 Spain Molecular Diagnostics Market, by End User
    • 11.2.36 Rest of Europe
      • 11.2.36.1 Overview
    • 11.2.37 Rest of Europe Molecular Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
    • 11.2.38 Rest of Europe Molecular Diagnostics Market, by Disease Area
    • 11.2.39 Rest of Europe Molecular Diagnostics Market, by Technology
      • 11.2.39.1 Rest of Europe Molecular Diagnostics Market, Polymerase Chain Reaction (PCR)
    • 11.2.40 Rest of Europe Molecular Diagnostics Market, by Product and Services
    • 11.2.41 Rest of Europe Molecular Diagnostics Market, by End User
  • 11.3 Asia Pacific Molecular Diagnostics Market, Revenue And Forecast to 2030
    • 11.3.1 Overview
    • 11.3.2 Asia Pacific Molecular Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
    • 11.3.3 Asia Pacific Molecular Diagnostics Market, by Disease Area
    • 11.3.4 Asia Pacific Molecular Diagnostics Market, by Technology
      • 11.3.4.1 Asia Pacific Molecular Diagnostics Market, Polymerase Chain Reaction (PCR)
    • 11.3.5 Asia Pacific Molecular Diagnostics Market, by Product and Services
    • 11.3.6 Asia Pacific Molecular Diagnostics Market, by End User
      • 11.3.6.1 Asia Pacific Molecular Diagnostics Market by Country
    • 11.3.7 China
      • 11.3.7.1 Overview
    • 11.3.8 China Molecular Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
    • 11.3.9 China Molecular Diagnostics Market, by Disease Area
    • 11.3.10 China Molecular Diagnostics Market, by Technology
      • 11.3.10.1 China Molecular Diagnostics Market, Polymerase Chain Reaction (PCR)
    • 11.3.11 China Molecular Diagnostics Market, by Product and Services
    • 11.3.12 China Molecular Diagnostics Market, by End User
    • 11.3.13 Japan
      • 11.3.13.1 Overview
    • 11.3.14 Japan Molecular Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
    • 11.3.15 Japan Molecular Diagnostics Market, by Disease Area
    • 11.3.16 Japan Molecular Diagnostics Market, by Technology
      • 11.3.16.1 Japan Molecular Diagnostics Market, Polymerase Chain Reaction (PCR)
    • 11.3.17 Japan Molecular Diagnostics Market, by Product and Services
    • 11.3.18 Japan Molecular Diagnostics Market, by End User
    • 11.3.19 India
      • 11.3.19.1 Overview
    • 11.3.20 India Molecular Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
    • 11.3.21 India Molecular Diagnostics Market, by Disease Area
    • 11.3.22 India Molecular Diagnostics Market, by Technology
      • 11.3.22.1 India Molecular Diagnostics Market, Polymerase Chain Reaction (PCR)
    • 11.3.23 India Molecular Diagnostics Market, by Product and Services
    • 11.3.24 India Molecular Diagnostics Market, by End User
    • 11.3.25 Australia
      • 11.3.25.1 Overview
    • 11.3.26 Australia Molecular Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
    • 11.3.27 Australia Molecular Diagnostics Market, by Disease Area
    • 11.3.28 Australia Molecular Diagnostics Market, by Technology
      • 11.3.28.1 Australia Molecular Diagnostics Market, Polymerase Chain Reaction (PCR)
    • 11.3.29 Australia Molecular Diagnostics Market, by Product and Services
    • 11.3.30 Australia Molecular Diagnostics Market, by End User
    • 11.3.31 South Korea
      • 11.3.31.1 Overview
    • 11.3.32 South Korea Molecular Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
    • 11.3.33 South Korea Molecular Diagnostics Market, by Disease Area
    • 11.3.34 South Korea Molecular Diagnostics Market, by Technology
      • 11.3.34.1 South Korea Molecular Diagnostics Market, Polymerase Chain Reaction (PCR)
    • 11.3.35 South Korea Molecular Diagnostics Market, by Product and Services
    • 11.3.36 South Korea Molecular Diagnostics Market, by End User
    • 11.3.37 Singapore
      • 11.3.37.1 Overview
    • 11.3.38 Singapore Molecular Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
    • 11.3.39 Singapore Molecular Diagnostics Market, by Disease Area
    • 11.3.40 Singapore Molecular Diagnostics Market, by Technology
      • 11.3.40.1 Singapore Molecular Diagnostics Market, Polymerase Chain Reaction (PCR)
    • 11.3.41 Singapore Molecular Diagnostics Market, by Product and Services
    • 11.3.42 Singapore Molecular Diagnostics Market, by End User
    • 11.3.43 Malaysia
      • 11.3.43.1 Overview
    • 11.3.44 Malaysia Molecular Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
    • 11.3.45 Malaysia Molecular Diagnostics Market, by Disease Area
    • 11.3.46 Malaysia Molecular Diagnostics Market, by Technology
      • 11.3.46.1 Malaysia Molecular Diagnostics Market, Polymerase Chain Reaction (PCR)
    • 11.3.47 Malaysia Molecular Diagnostics Market, by Product and Services
    • 11.3.48 Malaysia Molecular Diagnostics Market, by End User
    • 11.3.49 Philippines
      • 11.3.49.1 Overview
    • 11.3.50 Philippines Molecular Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
    • 11.3.51 Philippines Molecular Diagnostics Market, by Disease Area
    • 11.3.52 Philippines Molecular Diagnostics Market, by Technology
      • 11.3.52.1 Philippines Molecular Diagnostics Market, Polymerase Chain Reaction (PCR)
    • 11.3.53 Philippines Molecular Diagnostics Market, by Product and Services
    • 11.3.54 Philippines Molecular Diagnostics Market, by End User
    • 11.3.55 Thailand
      • 11.3.55.1 Overview
    • 11.3.56 Thailand Molecular Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
    • 11.3.57 Thailand Molecular Diagnostics Market, by Disease Area
    • 11.3.58 Thailand Molecular Diagnostics Market, by Technology
      • 11.3.58.1 Thailand Molecular Diagnostics Market, Polymerase Chain Reaction (PCR)
    • 11.3.59 Thailand Molecular Diagnostics Market, by Product and Services
    • 11.3.60 Thailand Molecular Diagnostics Market, by End User
    • 11.3.61 Indonesia
      • 11.3.61.1 Overview
    • 11.3.62 Indonesia Molecular Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
    • 11.3.63 Indonesia Molecular Diagnostics Market, by Disease Area
    • 11.3.64 Indonesia Molecular Diagnostics Market, by Technology
      • 11.3.64.1 Indonesia Molecular Diagnostics Market, Polymerase Chain Reaction (PCR)
    • 11.3.65 Indonesia Molecular Diagnostics Market, by Product and Services
    • 11.3.66 Indonesia Molecular Diagnostics Market, by End User
    • 11.3.67 Vietnam
      • 11.3.67.1 Overview
    • 11.3.68 Vietnam Molecular Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
    • 11.3.69 Vietnam Molecular Diagnostics Market, by Disease Area
    • 11.3.70 Vietnam Molecular Diagnostics Market, by Technology
      • 11.3.70.1 Vietnam Molecular Diagnostics Market, Polymerase Chain Reaction (PCR)
    • 11.3.71 Vietnam Molecular Diagnostics Market, by Product and Services
    • 11.3.72 Vietnam Molecular Diagnostics Market, by End User
    • 11.3.73 Rest of Asia Pacific
      • 11.3.73.1 Overview
    • 11.3.74 Rest of Asia Pacific Molecular Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
    • 11.3.75 Rest of Asia Pacific Molecular Diagnostics Market, by Disease Area
    • 11.3.76 Rest of Asia Pacific Molecular Diagnostics Market, by Technology
      • 11.3.76.1 Rest of Asia Pacific Molecular Diagnostics Market, Polymerase Chain Reaction (PCR)
    • 11.3.77 Rest of Asia Pacific Molecular Diagnostics Market, by Product and Services
    • 11.3.78 Rest of Asia Pacific Molecular Diagnostics Market, by End User
  • 11.4 Middle East & Africa Molecular Diagnostics Market, Revenue And Forecast to 2030
    • 11.4.1 Overview
    • 11.4.2 Middle East & Africa Molecular Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
    • 11.4.3 Middle East & Africa Molecular Diagnostics Market, by Disease Area
    • 11.4.4 Middle East & Africa Molecular Diagnostics Market, by Technology
      • 11.4.4.1 Middle East & Africa Molecular Diagnostics Market, Polymerase Chain Reaction (PCR)
    • 11.4.5 Middle East & Africa Molecular Diagnostics Market, by Product and Services
    • 11.4.6 Middle East & Africa Molecular Diagnostics Market, by End User
      • 11.4.6.1 Middle East & Africa Molecular Diagnostics Market by Country
    • 11.4.7 UAE
      • 11.4.7.1 Overview
    • 11.4.8 UAE Molecular Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
    • 11.4.9 UAE Molecular Diagnostics Market, by Disease Area
    • 11.4.10 UAE Molecular Diagnostics Market, by Technology
      • 11.4.10.1 UAE Molecular Diagnostics Market, Polymerase Chain Reaction (PCR)
    • 11.4.11 UAE Molecular Diagnostics Market, by Product and Services
    • 11.4.12 UAE Molecular Diagnostics Market, by End User
    • 11.4.13 Saudi Arabia
      • 11.4.13.1 Overview
    • 11.4.14 Saudi Arabia Molecular Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
    • 11.4.15 Saudi Arabia Molecular Diagnostics Market, by Disease Area
    • 11.4.16 Saudi Arabia Molecular Diagnostics Market, by Technology
      • 11.4.16.1 Saudi Arabia Molecular Diagnostics Market, Polymerase Chain Reaction (PCR)
    • 11.4.17 Saudi Arabia Molecular Diagnostics Market, by Product and Services
    • 11.4.18 Saudi Arabia Molecular Diagnostics Market, by End User
    • 11.4.19 South Africa
      • 11.4.19.1 Overview
    • 11.4.20 South Africa Molecular Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
    • 11.4.21 South Africa Molecular Diagnostics Market, by Disease Area
    • 11.4.22 South Africa Molecular Diagnostics Market, by Technology
      • 11.4.22.1 South Africa Molecular Diagnostics Market, Polymerase Chain Reaction (PCR)
    • 11.4.23 South Africa Molecular Diagnostics Market, by Product and Services
    • 11.4.24 South Africa Molecular Diagnostics Market, by End User
    • 11.4.25 Rest of Middle East & Africa
      • 11.4.25.1 Overview
    • 11.4.26 Rest of Middle East & Africa Molecular Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
    • 11.4.27 Rest of Middle East & Africa Molecular Diagnostics Market, by Disease Area
    • 11.4.28 Rest of Middle East & Africa Molecular Diagnostics Market, by Technology
      • 11.4.28.1 Rest of Middle East & Africa Molecular Diagnostics Market, Polymerase Chain Reaction (PCR)
    • 11.4.29 Rest of Middle East & Africa Molecular Diagnostics Market, by Product and Services
    • 11.4.30 Rest of Middle East & Africa Molecular Diagnostics Market, by End User
  • 11.5 South & Central America Molecular Diagnostics Market, Revenue And Forecast to 2030
    • 11.5.1 Overview
    • 11.5.2 South & Central America Molecular Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
    • 11.5.3 South & Central America Molecular Diagnostics Market, by Disease Area
    • 11.5.4 South & Central America Molecular Diagnostics Market, by Technology
      • 11.5.4.1 South & Central America Molecular Diagnostics Market, Polymerase Chain Reaction (PCR)
    • 11.5.5 South & Central America Molecular Diagnostics Market, by Product and Services
    • 11.5.6 South & Central America Molecular Diagnostics Market, by End User
      • 11.5.6.1 South & Central America Molecular Diagnostics Market by Country
    • 11.5.7 Brazil
      • 11.5.7.1 Overview
    • 11.5.8 Brazil Molecular Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
    • 11.5.9 Brazil Molecular Diagnostics Market, by Disease Area
    • 11.5.10 Brazil Molecular Diagnostics Market, by Technology
      • 11.5.10.1 Brazil Molecular Diagnostics Market, Polymerase Chain Reaction (PCR)
    • 11.5.11 Brazil Molecular Diagnostics Market, by Product and Services
    • 11.5.12 Brazil Molecular Diagnostics Market, by End User
    • 11.5.13 Argentina
      • 11.5.13.1 Overview
    • 11.5.14 Argentina Molecular Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
    • 11.5.15 Argentina Molecular Diagnostics Market, by Disease Area
    • 11.5.16 Argentina Molecular Diagnostics Market, by Technology
      • 11.5.16.1 Argentina Molecular Diagnostics Market, Polymerase Chain Reaction (PCR)
    • 11.5.17 Argentina Molecular Diagnostics Market, by Product and Services
    • 11.5.18 Argentina Molecular Diagnostics Market, by End User
    • 11.5.19 Rest of South & Central America
      • 11.5.19.1 Overview
    • 11.5.20 Rest of South & Central America Molecular Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
    • 11.5.21 Rest of South & Central America Molecular Diagnostics Market, by Disease Area
    • 11.5.22 Rest of South & Central America Molecular Diagnostics Market, by Technology
      • 11.5.22.1 Rest of South & Central America Molecular Diagnostics Market, Polymerase Chain Reaction (PCR)
    • 11.5.23 Rest of South & Central America Molecular Diagnostics Market, by Product and Services
    • 11.5.24 Rest of South & Central America Molecular Diagnostics Market, by End User

12. Pre & Post Covid-19 Impact

  • 12.1 Pre & Post Covid-19 Impact

13. Molecular Diagnostics Market Industry Landscape

  • 13.1 Overview
  • 13.2 Growth Strategies Done by the Companies in the Market (%)
  • 13.3 Organic Developments
    • 13.3.1 Overview
  • 13.4 Inorganic Developments
    • 13.4.1 Overview

14. Molecular Diagnostics Market, Key Company Profiles

  • 14.1 Abbott Laboratories
    • 14.1.1 Key Facts
    • 14.1.2 Business Description
    • 14.1.3 Products and Services
    • 14.1.4 Financial Overview
    • 14.1.5 SWOT Analysis
    • 14.1.6 Key Developments
  • 14.2 Agilent Technologies Inc
    • 14.2.1 Key Facts
    • 14.2.2 Business Description
    • 14.2.3 Products and Services
    • 14.2.4 Financial Overview
    • 14.2.5 SWOT Analysis
    • 14.2.6 Key Developments
  • 14.3 Thermo Fisher Scientific Inc
    • 14.3.1 Key Facts
    • 14.3.2 Business Description
    • 14.3.3 Products and Services
    • 14.3.4 Financial Overview
    • 14.3.5 SWOT Analysis
    • 14.3.6 Key Developments
  • 14.4 F. Hoffmann-La Roche Ltd
    • 14.4.1 Key Facts
    • 14.4.2 Business Description
    • 14.4.3 Products and Services
    • 14.4.4 Financial Overview
    • 14.4.5 SWOT Analysis
    • 14.4.6 Key Developments
  • 14.5 Qiagen NV
    • 14.5.1 Key Facts
    • 14.5.2 Business Description
    • 14.5.3 Products and Services
    • 14.5.4 Financial Overview
    • 14.5.5 SWOT Analysis
    • 14.5.6 Key Developments
  • 14.6 bioMerieux SA
    • 14.6.1 Key Facts
    • 14.6.2 Business Description
    • 14.6.3 Products and Services
    • 14.6.4 Financial Overview
    • 14.6.5 SWOT Analysis
    • 14.6.6 Key Developments
  • 14.7 Illumina Inc
    • 14.7.1 Key Facts
    • 14.7.2 Business Description
    • 14.7.3 Products and Services
    • 14.7.4 Financial Overview
    • 14.7.5 SWOT Analysis
    • 14.7.6 Key Developments
  • 14.8 Danaher
    • 14.8.1 Key Facts
    • 14.8.2 Business Description
    • 14.8.3 Products and Services
    • 14.8.4 Financial Overview
    • 14.8.5 SWOT Analysis
    • 14.8.6 Key Developments
  • 14.9 Siemens Healthineers AG
    • 14.9.1 Key Facts
    • 14.9.2 Business Description
    • 14.9.3 Products and Services
    • 14.9.4 Financial Overview
    • 14.9.5 SWOT Analysis
    • 14.9.6 Key Developments
  • 14.10 Novartis AG
    • 14.10.1 Key Facts
    • 14.10.2 Business Description
    • 14.10.3 Products and Services
    • 14.10.4 Financial Overview
    • 14.10.5 SWOT Analysis
    • 14.10.6 Key Developments
  • 14.11 TBG Diagnostics Limited
    • 14.11.1 Key Facts
    • 14.11.2 Business Description
    • 14.11.3 Products and Services
    • 14.11.4 Financial Overview
    • 14.11.5 SWOT Analysis
    • 14.11.6 Key Developments

15. Appendix

  • 15.1 About Us
  • 15.2 Glossary of Terms
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제